Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review
Gooderham, M.; Posso-De Los Rios, C.J.; Rubio-Gomez, G.A.; Papp, K.
Skin Therapy Letter 20(1): 1-5
2015
ISSN/ISBN: 1201-5989 PMID: 25807214 Document Number: 685221
Acting on keratinocytes to produce antimicrobial peptides and chemokines, which in turn attract neutrophils and other inflammatory cells, interleukin-17 (IL-17) is believed to be a potent driver of plaque psoriasis. Its proinflammatory characteristics make IL-17 an attractive therapeutic target for addressing immune dysregulation. This review examines the role of IL-17 in the pathogenesis of plaque psoriasis and the potential implications of its inhibition. The efficacy and safety results from Phase 2 and 3 trials with monoclonal antibodies targeting IL-17RA (brodalumab), and IL-17A (ixekizumab and secukinumab) validate IL-17 as an effective therapeutic target for the treatment of plaque psoriasis.